



NEWS RELEASE

Not for distribution in the United States or to U.S. newswire services

ALPHA COGNITION ANNOUNCES CSE LISTING AND TSXV DE-LISTING

April 27, 2023 – Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“**Alpha Cognition**”, or the “**Company**”) is pleased to announce that it has received conditional approval to list its common shares and its listed warrants on the Canadian Securities Exchange (the “**CSE**”). In connection with the listing the Company will voluntarily delist its common shares and listed warrants from the TSX Venture Exchange (the “**TSXV**”).

The Company’s shares and listed warrants are expected to commence trading on the CSE on May 1, 2023. The Company’s trading symbols “ACOG” and “ACOG.WT” will remain unchanged. The shares and listed warrants will be delisted from the TSXV at the close of trading on April 28, 2023. The Company’s shares will continue to be quoted on the OTCQB under the symbol ACOGF.

About Alpha Cognition Inc.

Alpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“**mTBI**”), for which there are currently no approved treatment options.

ALPHA-1062, is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ALPHA-1062’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI.

For further information:

info@alphacognition.com
<https://www.alphacognition.com/>

No stock exchange, nor the OTC Markets Group or any stock exchange Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.



Forward-looking Statements

This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward-looking statement that reflects the Company's current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the words "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "target," "seek," "contemplate," "continue" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements may include statements regarding delisting from the TSXV, listed on the CSE, the Company's business strategy, market size, potential growth opportunities, capital requirements, clinical development activities, the timing and results of clinical trials, regulatory submissions, potential regulatory approval and commercialization of the Company's products. Although the Company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward-looking statements for any reason, even if new information becomes available in the future.